Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy.

Abstract:

BACKGROUND:Neutrophil-to-lymphocyte ratio (NLR) might reflect an increased neutrophilic inflammatory response, and urothelial tumors with squamous-cell features (SqD) have been linked to inflammation. We hypothesized that NLR could be prognostic in these patients. PATIENTS AND METHODS:In patients with SqD muscle-invasive bladder cancer treated with curative intent, NLR and relationships with outcomes were analyzed by Cox regression, log-rank, and Kaplan-Meier analysis. RESULTS:Fifty patients presented SqD (median follow-up, 29 months). The ideal NLR cutoff (by receiver operating characteristic curves) was 5. Thirty-seven patients had NLR < 5 and 13 had NLR ≥ 5. The 5-year progression-free survival, cancer-specific survival (CSS), and overall survival were 46.8%, 48.4%, and 45% for NLR < 5 cases, and 10.3%, 10.3%, and 11.7% for NLR ≥ 5 cases (all P < .05). On multivariate analysis, NLR was prognostic (hazard ratio = 4.26, 6.21, and 4.08 for progression-free survival, CSS, and overall survival). Neoadjuvant chemotherapy (NAC) was of significant benefit in NLR < 5 patients, with a CSS of 91.2 months (n = 3) versus 38.1 months (n = 24) for those treated with up-front radical cystectomy (P = .009); Kaplan-Meier curves were also significantly different. These differences did not reach statistical significance for patients with NLR ≥ 5. For the 19 patients treated with NAC, NLR was also predictive of response to NAC. CONCLUSION:Inflammation, measured by NLR, is potentially prognostic in the perioperative management of SqD. NLR identifies 2 risk groups. Patients displaying low NLR had a 4-fold survival improvement and were highly responsive to NAC. NLR might be a good prognostic tool. Its role as a predictor of response to NAC deserves future study, along with its role as a selection criterion for therapies other than chemotherapy.

journal_name

Clin Genitourin Cancer

authors

Buisan O,Orsola A,Oliveira M,Martinez R,Etxaniz O,Areal J,Ibarz L

doi

10.1016/j.clgc.2017.01.024

subject

Has Abstract

pub_date

2017-08-01 00:00:00

pages

e697-e706

issue

4

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(17)30040-X

journal_volume

15

pub_type

杂志文章
  • Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.

    abstract:BACKGROUND:Hyperglycemia and hypercholesterolemia are class effects of mammalian target of rapamycin inhibitors. The purpose of this study was to characterize safety and efficacy of patients with metastatic renal cell carcinoma (mRCC) treated with everolimus in RECORD-1 (REnal Cell cancer treatment with Oral RAD001 giv...

    journal_title:Clinical genitourinary cancer

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clgc.2016.04.011

    authors: Bono P,Oudard S,Bodrogi I,Hutson TE,Escudier B,Machiels JP,Thompson JA,Figlin RA,Ravaud A,Basaran M,Porta C,Bracarda S,Brechenmacher T,Lin C,Voi M,Grunwald V,Motzer RJ

    更新日期:2016-10-01 00:00:00

  • Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.

    abstract:BACKGROUND:Venous thromboembolic events (VTEs) frequently occur in cancer patients. Risk assessment models (RAMs) for cancer-associated thrombosis have been proposed. However, advanced urinary tract cancer (aUTC) was not adequately represented in these models. We studied the incidence of VTEs, the risk factors, and the...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.12.021

    authors: Bamias A,Tzannis K,Dimitriadis I,Tsironis G,Papatheorodidi AM,Tsiara A,Fragkoulis C,Xirokosta A,Barbarousi D,Papadopoulos G,Zakopoulou R,Varkarakis I,Mitsogiannis I,Adamakis I,Alamanis C,Stravodimos K,Papatsoris AG,Dell

    更新日期:2020-08-01 00:00:00

  • Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.

    abstract:BACKGROUND:Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. PATIENTS AND METHODS:This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by patho...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2018.07.028

    authors: Ito K,Mikami S,Tatsugami K,Masumori N,Shinohara N,Kondo T,Nakanishi S,Nagashima Y,Eto M,Kamba T,Kuroda N,Tomita Y,Matsuyama H,Onishi T,Tsushima T,Nakazawa H,Oya M,Ozono S,Naito S,Asano T

    更新日期:2018-12-01 00:00:00

  • Evaluation of Gleason Grade Group 5 in a Contemporary Prostate Cancer Grading System and Literature Review.

    abstract:INTRODUCTION:The aim of this study was to validate contemporary grading systems, in particular, the Gleason grade group (GGG) 5. PATIENTS AND METHODS:We retrospectively reviewed the clinicopathologic data of 176 patients who underwent radical prostatectomy and whose pathologic results were GGG 4 or 5. The endpoints we...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2020.08.001

    authors: Kamitani R,Matsumoto K,Kosaka T,Takeda T,Hashiguchi A,Tanaka N,Morita S,Mizuno R,Shinojima T,Asanuma H,Oya M

    更新日期:2020-08-07 00:00:00

  • Bladder Cancer Stage Development, 2004-2014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort.

    abstract:BACKGROUND:The purpose of this study was to analyze trends of bladder cancer (BC) stages and incidence in Europe and the United States (US). MATERIALS AND METHODS:Tumor stages after radical cystectomy were assessed in a monocentric cohort from 2006 to 2016. BC incidence was assessed between 2004 and 2014 based on the ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.10.008

    authors: Schulz GB,Grimm T,Buchner A,Jokisch F,Kretschmer A,Stief CG,Knüchel R,Kraywinkel K,Karl A

    更新日期:2020-06-01 00:00:00

  • Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.

    abstract::The use of sunitinib in dialysis patients is poorly described but is of clinical importance. We report 2 cases of patients receiving sunitinib for metastatic renal cell carcinoma while undergoing dialysis. The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue a...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2009.n.035

    authors: Vickers MM,Heng DY,Hemmelgarn B,Eigl BJ

    更新日期:2009-10-01 00:00:00

  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

    abstract::Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was con...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CGC.2008.n.023

    authors: Sonpavde G,Hutson TE,Berry WR,Boehm KA,Asmar L

    更新日期:2008-09-01 00:00:00

  • What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?

    abstract:BACKGROUND:In this study we aimed to determine the relationship between prostate-specific antigen (PSA)-related information obtained from the provider and PSA test uptake. With recent focus on patient-provider communication (PC) and the guidelines recommending against PSA tests for prostate cancer (PCa), PC regarding t...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.05.002

    authors: Haider MR,Qureshi ZP,Horner R,Friedman DB,Bennett C

    更新日期:2017-12-01 00:00:00

  • Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

    abstract:BACKGROUND:We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy. PATIENTS AND METHODS:Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using r...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.03.006

    authors: Kohli M,Oberg AL,Mahoney DW,Riska SM,Sherwood R,Zhang Y,Zenka RM,Sahasrabudhe D,Qin R,Zhang S

    更新日期:2019-08-01 00:00:00

  • Development of a Novel Prognostic Risk Score for Predicting Complications of Penectomy in the Surgical Management of Penile Cancer.

    abstract:INTRODUCTION:Penectomy for PC is useful in staging, disease prognosis, and treatment. Limited studies have evaluated its surgical complications. We sought to assess these complications and determine predictive models to create a novel risk score for penectomy complications. PATIENTS AND METHODS:A retrospective review ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.018

    authors: Velazquez N,Press B,Renson A,Wysock JS,Taneja S,Huang WC,Bjurlin MA

    更新日期:2019-02-01 00:00:00

  • Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer.

    abstract:BACKGROUND:The objective of this study was to investigate positive surgical margin (PSM) rates in patients with prostate cancer treated with radical prostatectomy (RP) and assess PSM impact on cancer-specific mortality (CSM). PATIENTS AND METHODS:Within the Surveillance, Epidemiology, and End Results (SEER) database (...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.024

    authors: Preisser F,Mazzone E,Knipper S,Nazzani S,Bandini M,Shariat SF,Tian Z,Saad F,Montorsi F,Zorn KC,Graefen M,Tilki D,Karakiewicz PI

    更新日期:2019-02-01 00:00:00

  • Utilization of Pelvic Lymph Node Dissection for Patients With Low-Risk Prostate Cancer Treated With Robot-Assisted Radical Prostatectomy.

    abstract:INTRODUCTION:Pelvic lymph node dissection (PLND) is not recommended for low-risk prostate cancer (PCa) patients. However, the rate of PLND in this population is unknown. METHODS:We queried the National Cancer Data Base for PCa patients who underwent robot-assisted radical prostatectomy from 2010 to 2013 and stratified...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.05.013

    authors: Modi PK,Bock M,Kim S,Singer EA,Parikh RR

    更新日期:2017-12-01 00:00:00

  • An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database.

    abstract:BACKGROUND:The purpose of this study was to analyze contemporary trends for diagnosis and treatment of upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS:We identified all cases of UTUC in the National Cancer Database (NCDB) between 2004 and 2013. Data comprising tumor, patient, and facility factors were ex...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.01.015

    authors: Browne BM,Stensland KD,Moynihan MJ,Canes D

    更新日期:2018-08-01 00:00:00

  • Stem cell origin of testicular seminoma.

    abstract:INTRODUCTION:A major question concerning cancer is its cells of origin. We hypothesized that distinct cancer subtypes arise from unique cancer-initiating cells. By performing a microarray meta-analysis of seminomas and spermatogonial stem cells, we investigated a putative cell of origin for seminoma. MATERIALS AND MET...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clgc.2013.04.015

    authors: Som A,Wen S,Tu SM

    更新日期:2013-12-01 00:00:00

  • Secondary hormonal therapy in men with castration-resistant prostate cancer.

    abstract:BACKGROUND:Androgen receptor (AR) signaling remains important in castration-resistant prostate cancer (CRPC) and sequential responses to hormonal therapies are observed. Little is known about the factors associated with responsiveness to secondary hormone therapy (HT). METHODS:We retrospectively identified patients wi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2011.06.006

    authors: Nakabayashi M,Werner L,Oh WK,Regan MM,Kantoff PW,Taplin ME

    更新日期:2011-12-01 00:00:00

  • Outcomes in Organ Transplant Recipients With Prostate Cancer Treated With Radiotherapy.

    abstract:BACKGROUND:Few data exist in the literature regarding outcomes of men with prostate cancer (CaP) who are receiving immunosuppression from prior organ transplantation. The aim of this study was to evaluate biochemical disease-free survival, distant metastasis-free survival, overall survival, and toxicity in patients wit...

    journal_title:Clinical genitourinary cancer

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clgc.2018.10.005

    authors: Oh SC,Tariq MB,Reddy CA,Ciezki JP,Stephans KL,Tendulkar RD

    更新日期:2019-02-01 00:00:00

  • Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.

    abstract:BACKGROUND:Combination platinum chemotherapy is standard first-line therapy for metastatic urothelial carcinoma (mUC). Defining the platinum response biomarkers for patients with mUC could establish personalize medicine and provide insights into mUC biology. Although DNA repair mechanisms have been hypothesized to medi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.12.029

    authors: Mullane SA,Werner L,Guancial EA,Lis RT,Stack EC,Loda M,Kantoff PW,Choueiri TK,Rosenberg J,Bellmunt J

    更新日期:2016-08-01 00:00:00

  • Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review.

    abstract::Nephrectomy is the reference-standard treatment for renal-cell carcinoma (RCC). For patients with unresectable disease, tumor may be shrunk by using chemotherapy, thereby permitting surgical resection, which can be curative. We provided neoadjuvant cabozantinib, the preferred tyrosine kinase inhibitor for advanced RCC...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2020.04.003

    authors: Roy AM,Briggler A,Tippit D,Dawson K,Verma R

    更新日期:2020-12-01 00:00:00

  • Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer.

    abstract:INTRODUCTION:The objective of this study was to examine the overall survival (OS) in patients diagnosed with high-grade T1 non-muscle-invasive bladder cancer treated with early radical cystectomy versus local treatment of the primary tumor, defined as endoscopic management with or without intravesical chemotherapy or i...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2020.03.013

    authors: Tully KH,Roghmann F,Noldus J,Chen X,Häuser L,Kibel AS,Sonpavde GP,Mossanen M,Trinh QD

    更新日期:2020-12-01 00:00:00

  • Human immunodeficiency virus--associated renal cell carcinoma: a transatlantic case series.

    abstract:OBJECTIVE:The spectrum of diseases associated with human immunodeficiency virus (HIV) infection has changed dramatically following the introduction of highly active antiretroviral therapy (HAART). Non-AIDS-defining cancers, including renal cell carcinoma (RCC), are being recognized increasingly in this population. Our ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2008.n.013

    authors: Gaughan EM,Dezube BJ,Aboulafia D,Bower M,Stebbing J,Powles T,Pantanowitz L

    更新日期:2008-09-01 00:00:00

  • Spontaneous intraperitoneal perforation of the bladder: a late complication of radiation therapy for prostate cancer.

    abstract::The spontaneous intraperitoneal rupture of the urinary bladder is an extremely rare and life-threatening event. Often, there are difficulties in establishing the diagnosis. A patient with spontaneous perforation of the urinary bladder, 17 years after successful treatment of an adenocarcinoma of the prostate by pelvic ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2007.n.006

    authors: Ketata S,Boulaire JL,Al-Ahdab N,Bargain A,Damamme A

    更新日期:2007-03-01 00:00:00

  • Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.

    abstract:INTRODUCTION:Oxidative stress has been found to be associated with the progression of prostate cancer (PCa); however, human studies which identify differential roles of each oxidation pathway in PCa progression are lacking. We aimed to identify which oxidative stress markers, specifically lipid and global oxidation and...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.09.014

    authors: Wu T,Kasper S,Wong RM,Bracken B

    更新日期:2020-04-01 00:00:00

  • Comparison of Laparoscopic and Robot-assisted Radical Cystectomy for Bladder Cancer: Perioperative and Oncologic Outcomes.

    abstract:BACKGROUND:The purpose of this study was to compare perioperative and oncologic outcomes between laparoscopic radical cystectomy (LRC) and robot-assisted radical cystectomy (RARC) for bladder cancer (BCa). MATERIALS AND METHODS:Patients who underwent LRC or RARC with curative intent for BCa between January 2011 and De...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.06.007

    authors: Su S,Gu L,Ma X,Li H,Wang B,Shi T,Zhang X

    更新日期:2019-10-01 00:00:00

  • Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.

    abstract:BACKGROUND:Everolimus is an approved agent for use after disease progression with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma. With recently published trials showing efficacy of nivolumab and cabozantinib in the second-line therapy...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.12.011

    authors: Patel SB,Stenehjem DD,Gill DM,Tantravahi SK,Agarwal AM,Hsu J,Vuong W,Pal SK,Agarwal N

    更新日期:2016-04-01 00:00:00

  • Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma.

    abstract:INTRODUCTION:The introduction of active new agents, such as small molecules and checkpoint inhibitors, for the treatment of metastatic renal-cell cancer (mRCC) is associated with a relevant increase in costs, and it is therefore important to strike a balance between the costs of treatment and the added value represente...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.02.006

    authors: Giuliani J,Bonetti A

    更新日期:2018-06-01 00:00:00

  • Primary extraosseous ewing sarcoma of the kidney with level III inferior vena cava thrombus.

    abstract::Ewing sarcoma typically presents as a skeletal-based tumor, with rare instances of peripheral primitive neuroectodermal tumor (PNET) arising in the soft tissues. Few examples of organ-based PNETs have been previously described in the literature. These tumors are exceedingly rare as a primary renal neoplasm. To our kno...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2009.n.032

    authors: Fergany AF,Dhar N,Budd GT,Skacel M,Garcia JA

    更新日期:2009-10-01 00:00:00

  • Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.

    abstract:BACKGROUND:Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostatic carcinoma. PATIENTS AND METHODS:Scatter factor/HGF levels in pretreatment plasma samples from 171 men with metastatic hormone-refractory prostate canc...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2006.n.006

    authors: Humphrey PA,Halabi S,Picus J,Sanford B,Vogelzang NJ,Small EJ,Kantoff PW

    更新日期:2006-03-01 00:00:00

  • Adjuvant therapy of renal cell carcinoma.

    abstract::Metastatic renal cell carcinoma (RCC) has a highly variable natural history and carries a dismal prognosis. Unlike many other tumors, RCC is generally unresponsive to cytotoxic, hormonal, and radiation adjuvant therapies after cytoreductive surgery. Different modalities of treatment have been tried and tested with mod...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CGC.2006.n.028

    authors: Yap TA,Eisen TG

    更新日期:2006-09-01 00:00:00

  • A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.

    abstract:BACKGROUND:Among men with high-risk non-metastatic castrate-resistant prostate cancer (nmCRPC), we used network meta-analysis to compare non-steroidal anti-androgens (NSAAs) and stratified class-level meta-analysis to identify subgroups with particular benefit from NSAAs with androgen deprivation therapy versus androge...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2020.02.005

    authors: Hird AE,Magee DE,Bhindi B,Ye XY,Chandrasekar T,Goldberg H,Klotz L,Fleshner N,Satkunasivam R,Klaassen Z,Wallis CJD

    更新日期:2020-10-01 00:00:00

  • A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.

    abstract:BACKGROUND:Consistent with other data sets, our own institutional series suggests that survival in patients aged ≥ 75 years with metastatic renal cell carcinoma (mRCC) is inferior to that in patients < 75 years. We sought to confirm these trends through exploration of the Surveillance, Epidemiology and End Results (SEE...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2013.04.011

    authors: Nelson RA,Vogelzang N,Pal SK

    更新日期:2013-09-01 00:00:00